Verified source report
STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
What happened
According to STAT’s source item, STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows, A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor progression by 65% in patients with lung cancer, according to Phase 3…
Context
The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-05-21T21:00:00+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows via STAT. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.
Source links
- STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract showsSTAT - 2026-05-21T21:00:00+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.